Korro Bio (KRRO) Cash & Current Investments (2018 - 2026)

Korro Bio's Cash & Current Investments history runs 9 years deep, the most recent figure standing at $114.0 million for Q1 2026.

• Quarterly Cash & Current Investments fell 0.86% year-over-year to $114.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $114.0 million (down 0.86% YoY) and the FY2025 annual result came in at $75.2 million, down 40.4% from the prior year.
• Cash & Current Investments was $114.0 million for Q1 2026 at Korro Bio, up from $75.2 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $169.8 million in Q4 2023 and bottomed at $36.9 million in Q4 2022.
• A 5-year average of $102.7 million and a median of $111.0 million in 2022 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2022 — Cash & Current Investments sank 71.74% — and 2023, when it surged 359.62%.
• Korro Bio's Cash & Current Investments stood at $36.9 million in 2022, then jumped by 359.62% to $169.8 million in 2023, then retreated by 25.72% to $126.1 million in 2024, then tumbled by 40.4% to $75.2 million in 2025, then jumped by 51.64% to $114.0 million in 2026.
• Business Quant data shows KRRO's Cash & Current Investments at $114.0 million in Q1 2026, $75.2 million in Q4 2025, and $92.5 million in Q3 2025.